- Gynecologic cancer
-
Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities
-
Hasan Brau-Figueroa, Eder Arango-Bravo, Denisse Castro-Eguiluz, Tatiana Galicia-Carmona, Leopoldo Abraham Lugo-Alferez, Ivette Cruz-Bautista, Roberto Jiménez-Lima, Lucely Cetina-Pérez
-
Cancer Res Treat. 2022;54(2):554-562. Published online August 10, 2021
-
DOI: https://doi.org/10.4143/crt.2021.375
-
-
 Abstract
 PDF Supplementary Material PubReader ePub
- Purpose
The standard treatment for locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy with cisplatin (CDDP) followed by brachytherapy. The presence of comorbidities are risk factors for nephrotoxicity and are associated with lower survival. Gemcitabine is a radiosensitizing drug that has shown efficacy and safety in this context. The effectiveness of concomitant chemoradiotherapy with gemcitabine was evaluated versus cisplatin in LACC patients with comorbidities and preserved renal function.
Materials and Methods
An observational, longitudinal and paired study was carried out that included patients treated between February 2003 and December 2015. The primary objectives were to evaluate response rates, progression-free survival, and overall survival; the secondary objectives were to evaluate toxicity and renal function.
Results
Sixty-three patients treated with gemcitabine at 300 mg/m2 weekly and 126 patients treated with CDDP 40 mg/m2 weekly were included. There were no significant differences in response rates and survival rates. Treatment with cisplatin presented a higher frequency of hematological toxicities, while gemcitabine presented a higher frequency of gastrointestinal toxicities. A decrease in glomerular filtration rate (GFR; baseline vs. 1-year post-treatment) was observed in the cisplatin group (p=0.002), while not in the gemcitabine group (p=0.667). In a multivariate analysis, it is observed that only CDDP correlates with the decrease in GFR (hazard ratio, 2.42; p=0.012).
Conclusion
In LACC patients with comorbidities, gemcitabine and CDDP show the same efficacy, with different toxicity profiles. Treatment with cisplatin is associated with a significant decrease in GFR during follow-up, compared to treatment with gemcitabine that does not decrease it.
-
Citations
Citations to this article as recorded by  - Medical nanoscale materials for virus-induced cervical cancer therapeutic modalities: For targeting delivery
Adane Adugna, Mamaru Getinet, Gashaw Azanaw Amare, Mohammed Jemal
OpenNano.2025; 21: 100221. CrossRef - The Long Term Effects of a 12‐Session Community Exercise Program on Health Measures in Cancer Patients
Isaac Oppong, Roozbeh Naemi
Aging and Cancer.2025;[Epub] CrossRef - Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction
Silvia Alarcón-Barrios, Julissa Luvián-Morales, Denisse Castro-Eguiluz, Merari Delgadillo-González, Brenda Olivia Lezcano-Velázquez, Eder Alexandro Arango-Bravo, Laura Flores-Cisneros, Sebastián Aguiar Rosas, Lucely Cetina-Pérez
Current Problems in Cancer.2024; 48: 101041. CrossRef - Association between body composition phenotypes and treatment toxicity in women with cervical cancer undergoing chemoradiotherapy
Mariah Azevedo Aredes, Nathália Silva de Paula, Gabriela Villaça Chaves
Nutrition.2024; 127: 112539. CrossRef - Older adults with cancer and common comorbidities—challenges and opportunities in improving their cancer treatment outcomes
Weiwei Chen, Rachel D Altshuler, Phil Daschner, Carolina Salvador Morales, Diane C St. Germain, Jennifer Guida, Pataje G S Prasanna, Jeffrey C Buchsbaum
JNCI: Journal of the National Cancer Institute.2024; 116(11): 1730. CrossRef
-
7,161
View
-
159
Download
-
3
Web of Science
-
5
Crossref
|
KCA
